Expertise in
3
conditions

Dr. Dustin Fraidenburg

Intensive Care Medicine
UI Health Lung Health Program
1801 W Taylor St Ste 3C, 
Chicago, IL 
Offers Telehealth
17 Years of Experience
Expertise in
3
conditions
UI Health Lung Health Program
1801 W Taylor St Ste 3C, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Dustin Fraidenburg is an Intensive Care Medicine provider in Chicago, Illinois. Dr. Fraidenburg has been practicing medicine for over 17 years is highly rated in 3 conditions, according to our data. His top areas of expertise are Pulmonary Hypertension, Cerebral Hypoxia, Pulmonary Veno-Occlusive Disease, and Systemic Sclerosis (SSc).

His clinical research consists of co-authoring 33 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year
2009
Specialties
Intensive Care Medicine
Licenses
Internal Medicine in IL
Hospital Affiliations
University Of Illinois Hospital And Clinics
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Zing Health
  • MEDICARE MAPD
  • MEDICARE SNP
View 7 Less Insurance Carriers -

Locations

UI Health Lung Health Program
1801 W Taylor St Ste 3C, Chicago, IL 60612
Other Locations
University of Illinois Hospital
1331 W 75th St, Naperville, IL 60540

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Terminated
Publish Date: June 11, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
Enrollment Status: Terminated
Publish Date: June 04, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Controlled, Open-labeled, Multi-center Clinical Trial to Evaluate the Safe and Effective Performance of the Lungpacer Diaphragm Pacing Therapy System in Patients Who Have Failed to Wean From Mechanical Ventilation.
A Randomized, Controlled, Open-labeled, Multi-center Clinical Trial to Evaluate the Safe and Effective Performance of the Lungpacer Diaphragm Pacing Therapy System in Patients Who Have Failed to Wean From Mechanical Ventilation.
Enrollment Status: Terminated
Publish Date: December 09, 2024
Intervention Type: Device
Study Phase: Not Applicable
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
Enrollment Status: Terminated
Publish Date: November 24, 2023
Intervention Type: Drug
Study Drug: Inhaled treprostinil solution
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
Enrollment Status: Completed
Publish Date: July 27, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
Enrollment Status: Terminated
Publish Date: November 10, 2020
Intervention Type: Drug
Study Phase: Phase 3
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
Enrollment Status: Terminated
Publish Date: October 22, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 6 Less Clinical Trials

33 Total Publications

Thrombomodulin protects against acute vascular and multiorgan injury in Sickle Cell disease.
Thrombomodulin protects against acute vascular and multiorgan injury in Sickle Cell disease.
Journal: JCI insight
Published: December 09, 2025
Similar Doctors
Expertise in
15
conditions
Dr. Daniel Dilling
Intensive Care Medicine
Expertise in
15
conditions
Dr. Daniel Dilling
Intensive Care Medicine

Loyola University Medical Center

2160 S 1st Ave, 
Maywood, IL 
 (7.7 miles away)
708-327-5864
Languages Spoken:
English
See accepted insurances

Daniel Dilling is an Intensive Care Medicine provider in Maywood, Illinois. Dr. Dilling is highly rated in 15 conditions, according to our data. His top areas of expertise are Lymphangioleiomyomatosis, Acute Interstitial Pneumonia, Idiopathic Pulmonary Fibrosis, Lung Transplant, and Gastrostomy.

Expertise in
7
conditions
Dr. Ayodeji Adegunsoye
Intensive Care Medicine
Expertise in
7
conditions
Dr. Ayodeji Adegunsoye
Intensive Care Medicine

University Of Chicago Medical Center

5841 S Maryland Ave, 
Chicago, IL 
 (7.7 miles away)
888-824-0200
Languages Spoken:
English
See accepted insurances

Ayodeji Adegunsoye is an Intensive Care Medicine provider in Chicago, Illinois. Dr. Adegunsoye is highly rated in 7 conditions, according to our data. His top areas of expertise are Acute Interstitial Pneumonia, Interstitial Lung Disease, Pulmonary Fibrosis, Hypersensitivity Pneumonitis, and Lung Transplant.

Expertise in
6
conditions
Dr. Babak Mokhlesi
Intensive Care Medicine
Expertise in
6
conditions
Dr. Babak Mokhlesi
Intensive Care Medicine

University Of Chicago Medical Center

5841 S Maryland Ave, 
Chicago, IL 
 (7.7 miles away)
773-702-1454
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Babak Mokhlesi is an Intensive Care Medicine provider in Chicago, Illinois. Dr. Mokhlesi is highly rated in 6 conditions, according to our data. His top areas of expertise are Obstructive Sleep Apnea, Obesity Hypoventilation Syndrome (OHS), Excessive Daytime Sleepiness, Central Sleep Apnea, and Adenoidectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Fraidenburg's expertise for a condition
ConditionClose
View All 14 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile